International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative

Alexander G. S. Oldroyd; Jeffrey P. Callen; Hector Chinoy; Lorinda Chung; David Fiorentino; Patrick Gordon; Pedro M. Machado; Neil McHugh; Albert Selva-O’Callaghan; Jens Schmidt; Sarah L. Tansley; Ruth Ann Vleugels; Victoria P. Werth; Anthony A. Amato; Helena Andersson; Lilia Andrade-Ortega; Dana Ascherman; Olivier Benveniste; Lorenzo Cavagna; Christina Charles-Shoeman; Benjamin F. Chong; Lisa Christopher-Stine; Jennie T. Clarke; Emma J. Crosbie; Philip A. J. Crosbie; Sonye Danoff; Maryam Dastmalchi; Marianne de Visser; Paul F. Dellaripa; Louise Pyndt Diederichsen; Mazen M. Dimachkie; Erik Ensrud; Floranne Ernste; D. Gareth R. Evans; Manabu Fujimoto; Ignacio Garcia-de la Torre; Abraham Garcia-Kutzbach; Zoltan Griger; Latika Gupta; Marie Hudson; Florenzo Iannone; David Isenberg; Joseph Jorizzo; Helen Kurtz; Masataka Kuwana; Vidya Limaye; Ingrid E. Lundberg; Andrew L. Mammen; Herman Mann; Frank Mastaglia; Lorna McWilliams; Christopher A. Mecoli; Federica Meloni; Frederick W. Miller; Siamak Moghadam-Kia; Sergey Moiseev; Yoshinao Muro; Melinda Nagy-Vincze; Clive Nayler; Merrilee Needham; Ichizo Nishino; Chester V. Oddis; Julie J. Paik; Joost Raaphorst; Lisa G. Rider; Jorge Rojas-Serrano; Lesley Ann Saketkoo; Adam Schiffenbauer; Samuel Katsuyuki Shinjo; Vineeta Shobha; Yeong-Wook Song; Tania Tillett; Yves Troyanov; Anneke J. van der Kooi; M. nica V. zquez-Del Mercado; Jiri Vencovsky; Qian Wang; Steven Ytterberg; Rohit Aggarwal

doi:https://doi.org/10.1038/s41584-023-01045-w

International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative

Alexander G. S. Oldroyd, Jeffrey P. Callen, Hector Chinoy, Lorinda Chung, David Fiorentino, Patrick Gordon, Pedro M. Machado, Neil McHugh, Albert Selva-O’Callaghan, Jens Schmidt, Sarah L. Tansley, Ruth Ann Vleugels, Victoria P. Werth, Anthony A. Amato, Helena Andersson, Lilia Andrade-Ortega, Dana Ascherman, Olivier Benveniste, Lorenzo Cavagna, Christina Charles-ShoemanBenjamin F. Chong, Lisa Christopher-Stine, Jennie T. Clarke, Emma J. Crosbie, Philip A. J. Crosbie, Sonye Danoff, Maryam Dastmalchi, Marianne de Visser, Paul F. Dellaripa, Louise Pyndt Diederichsen, Mazen M. Dimachkie, Erik Ensrud, Floranne Ernste, D. Gareth R. Evans, Manabu Fujimoto, Ignacio Garcia-de la Torre, Abraham Garcia-Kutzbach, Zoltan Griger, Latika Gupta, Marie Hudson, Florenzo Iannone, David Isenberg, Joseph Jorizzo, Helen Kurtz, Masataka Kuwana, Vidya Limaye, Ingrid E. Lundberg, Andrew L. Mammen, Herman Mann, Frank Mastaglia, Lorna McWilliams, Christopher A. Mecoli, Federica Meloni, Frederick W. Miller, Siamak Moghadam-Kia, Sergey Moiseev, Yoshinao Muro, Melinda Nagy-Vincze, Clive Nayler, Merrilee Needham, Ichizo Nishino, Chester V. Oddis, Julie J. Paik, Joost Raaphorst, Lisa G. Rider, Jorge Rojas-Serrano, Lesley Ann Saketkoo, Adam Schiffenbauer, Samuel Katsuyuki Shinjo, Vineeta Shobha, Yeong-Wook Song, Tania Tillett, Yves Troyanov, Anneke J. van der Kooi, M. nica V. zquez-Del Mercado, Jiri Vencovsky, Qian Wang, Steven Ytterberg, Rohit Aggarwal

Research output: Contribution to journal › Article › Academic › peer-review

2 Citations (Scopus)

Abstract

Adult-onset idiopathic inflammatory myopathy (IIM) is associated with an increased cancer risk within the 3 years preceding and following IIM onset. Evidence- and consensus-based recommendations for IIM-associated cancer screening can potentially improve outcomes. This International Guideline for IIM-Associated Cancer Screening provides recommendations addressing IIM-associated cancer risk stratification, cancer screening modalities and screening frequency. The international Expert Group formed a total of 18 recommendations via a modified Delphi approach using a series of online surveys. First, the recommendations enable an individual patient’s IIM-associated cancer risk to be stratified into standard, moderate or high risk according to the IIM subtype, autoantibody status and clinical features. Second, the recommendations outline a ‘basic’ screening panel (including chest radiography and preliminary laboratory tests) and an ‘enhanced’ screening panel (including CT and tumour markers). Third, the recommendations advise on the timing and frequency of screening via basic and enhanced panels, according to risk status. The recommendations also advise consideration of upper or lower gastrointestinal endoscopy, nasoendoscopy and 18F-FDG PET–CT scanning in specific patient populations. These recommendations are aimed at facilitating earlier IIM-associated cancer detection, especially in those who are at a high risk, thus potentially improving outcomes, including survival.

Original language	English
Pages (from-to)	805-817
Number of pages	13
Journal	Nature Reviews Rheumatology
Volume	19
Issue number	12
Early online date	2023
DOIs	https://doi.org/10.1038/s41584-023-01045-w
Publication status	Published - Dec 2023

Access to Document

https://doi.org/10.1038/s41584-023-01045-w

Cite this

Oldroyd, A. G. S., Callen, J. P., Chinoy, H., Chung, L., Fiorentino, D., Gordon, P., Machado, P. M., McHugh, N., Selva-O’Callaghan, A., Schmidt, J., Tansley, S. L., Vleugels, R. A., Werth, V. P., Amato, A. A., Andersson, H., Andrade-Ortega, L., Ascherman, D., Benveniste, O., Cavagna, L., ... Aggarwal, R. (2023). International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative. Nature Reviews Rheumatology, 19(12), 805-817. https://doi.org/10.1038/s41584-023-01045-w

@article{9000db0d107d4267982d4055ad3690e0,

title = "International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative",

abstract = "Adult-onset idiopathic inflammatory myopathy (IIM) is associated with an increased cancer risk within the 3 years preceding and following IIM onset. Evidence- and consensus-based recommendations for IIM-associated cancer screening can potentially improve outcomes. This International Guideline for IIM-Associated Cancer Screening provides recommendations addressing IIM-associated cancer risk stratification, cancer screening modalities and screening frequency. The international Expert Group formed a total of 18 recommendations via a modified Delphi approach using a series of online surveys. First, the recommendations enable an individual patient{\textquoteright}s IIM-associated cancer risk to be stratified into standard, moderate or high risk according to the IIM subtype, autoantibody status and clinical features. Second, the recommendations outline a {\textquoteleft}basic{\textquoteright} screening panel (including chest radiography and preliminary laboratory tests) and an {\textquoteleft}enhanced{\textquoteright} screening panel (including CT and tumour markers). Third, the recommendations advise on the timing and frequency of screening via basic and enhanced panels, according to risk status. The recommendations also advise consideration of upper or lower gastrointestinal endoscopy, nasoendoscopy and 18F-FDG PET–CT scanning in specific patient populations. These recommendations are aimed at facilitating earlier IIM-associated cancer detection, especially in those who are at a high risk, thus potentially improving outcomes, including survival.",

author = "Oldroyd, {Alexander G. S.} and Callen, {Jeffrey P.} and Hector Chinoy and Lorinda Chung and David Fiorentino and Patrick Gordon and Machado, {Pedro M.} and Neil McHugh and Albert Selva-O{\textquoteright}Callaghan and Jens Schmidt and Tansley, {Sarah L.} and Vleugels, {Ruth Ann} and Werth, {Victoria P.} and Amato, {Anthony A.} and Helena Andersson and Lilia Andrade-Ortega and Dana Ascherman and Olivier Benveniste and Lorenzo Cavagna and Christina Charles-Shoeman and Chong, {Benjamin F.} and Lisa Christopher-Stine and Clarke, {Jennie T.} and Crosbie, {Emma J.} and Crosbie, {Philip A. J.} and Sonye Danoff and Maryam Dastmalchi and {de Visser}, Marianne and Dellaripa, {Paul F.} and Diederichsen, {Louise Pyndt} and Dimachkie, {Mazen M.} and Erik Ensrud and Floranne Ernste and Evans, {D. Gareth R.} and Manabu Fujimoto and {Garcia-de la Torre}, Ignacio and Abraham Garcia-Kutzbach and Zoltan Griger and Latika Gupta and Marie Hudson and Florenzo Iannone and David Isenberg and Joseph Jorizzo and Helen Kurtz and Masataka Kuwana and Vidya Limaye and Lundberg, {Ingrid E.} and Mammen, {Andrew L.} and Herman Mann and Frank Mastaglia and Lorna McWilliams and Mecoli, {Christopher A.} and Federica Meloni and Miller, {Frederick W.} and Siamak Moghadam-Kia and Sergey Moiseev and Yoshinao Muro and Melinda Nagy-Vincze and Clive Nayler and Merrilee Needham and Ichizo Nishino and Oddis, {Chester V.} and Paik, {Julie J.} and Joost Raaphorst and Rider, {Lisa G.} and Jorge Rojas-Serrano and Saketkoo, {Lesley Ann} and Adam Schiffenbauer and Shinjo, {Samuel Katsuyuki} and Vineeta Shobha and Yeong-Wook Song and Tania Tillett and Yves Troyanov and {van der Kooi}, {Anneke J.} and Mercado, {M. nica V. zquez-Del} and Jiri Vencovsky and Qian Wang and Steven Ytterberg and Rohit Aggarwal",

note = "Funding Information: This Evidence-Based Guideline was developed and conducted under the auspices of the International Myositis Assessment and Clinical Studies Group (IMACS). R.A. conceived the guideline development process. A.G.S.O. carried out survey question design, distribution and response collation. A.G.S.O and R.A. led the preparation of the manuscript, which was critically appraised and amended by all co-authors. All co-authors completed the surveys that led to the formation of the recommendations. The authors would like to acknowledge A.B. Allard, M.D. George, K. Kolstad, D.J.B. Kurtzman and A. Postolova, who provided input on the systematic literature review and meta-analysis, which formed key evidence for the development of the recommendations. The authors would like to acknowledge the invaluable input from three patient partners (two of whom are listed as authors, one of whom opted to remain anonymous) during the guideline planning, development and manuscript writing. The authors thank members of the IMACS Scientific Committee for critical reading of the manuscript. The authors thank H. Kim and I. Pinal Fern{\'a}ndez for critical reading of the manuscript and for providing helpful comments as part of the NIH internal review process. This report includes independent research supported by the National Institute for Health Research (NIHR) Biomedical Research Centre Funding Scheme. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, NIHR or the Department of Health and Social Care. A.G.S.O is supported by funding from the NIHR Clinical Lectureship Scheme. A.G.S.O, H.C., E.J.C., D.G.R.E., L.McW. and P.A.J.C are supported by the NIHR Manchester Biomedical Research Centre (NIHR203308). P.M.M is supported by funding from the NIHR University College London Hospitals Biomedical Research Centre. S.L.T. is supported by funding from the Bath Institute of Rheumatic Diseases. E.J.C. is supported by an NIHR Advanced Fellowship (NIHR300650). This research was supported in part by the Intramural Research Programs of the NIH, National Institute of Environmental Health Sciences (to L.G.R., F.W.M. and A.S.), and National Institute of Arthritis and Musculoskeletal and Skin Diseases (to A.L.M.). J.J.P. is supported by funding from the NIH (K23AR073927). M.V.-D.M. is supported by funding from Fondo de Desarrollo Cientifico (FODECIJAL) 2019 from Consejo Estatal de Ciencia y Tecnolog{\'i}a de Jalisco (COECYTJAL, 1702512-8152). J.V. is supported by funding from the Czech Ministry of Health — Conceptual Development of Research Organization 00023728 (Institute of Rheumatology). Publisher Copyright: {\textcopyright} 2023, Springer Nature Limited.",

year = "2023",

month = dec,

doi = "https://doi.org/10.1038/s41584-023-01045-w",

language = "English",

volume = "19",

pages = "805--817",

journal = "Nature Reviews Rheumatology",

issn = "1759-4790",

publisher = "Nature Publishing Group",

number = "12",

}

Oldroyd, AGS, Callen, JP, Chinoy, H, Chung, L, Fiorentino, D, Gordon, P, Machado, PM, McHugh, N, Selva-O’Callaghan, A, Schmidt, J, Tansley, SL, Vleugels, RA, Werth, VP, Amato, AA, Andersson, H, Andrade-Ortega, L, Ascherman, D, Benveniste, O, Cavagna, L, Charles-Shoeman, C, Chong, BF, Christopher-Stine, L, Clarke, JT, Crosbie, EJ, Crosbie, PAJ, Danoff, S, Dastmalchi, M, de Visser, M, Dellaripa, PF, Diederichsen, LP, Dimachkie, MM, Ensrud, E, Ernste, F, Evans, DGR, Fujimoto, M, Garcia-de la Torre, I, Garcia-Kutzbach, A, Griger, Z, Gupta, L, Hudson, M, Iannone, F, Isenberg, D, Jorizzo, J, Kurtz, H, Kuwana, M, Limaye, V, Lundberg, IE, Mammen, AL, Mann, H, Mastaglia, F, McWilliams, L, Mecoli, CA, Meloni, F, Miller, FW, Moghadam-Kia, S, Moiseev, S, Muro, Y, Nagy-Vincze, M, Nayler, C, Needham, M, Nishino, I, Oddis, CV, Paik, JJ, Raaphorst, J, Rider, LG, Rojas-Serrano, J, Saketkoo, LA, Schiffenbauer, A, Shinjo, SK, Shobha, V, Song, Y-W, Tillett, T, Troyanov, Y, van der Kooi, AJ, Mercado, MNVZ-D, Vencovsky, J, Wang, Q, Ytterberg, S & Aggarwal, R 2023, 'International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative', Nature Reviews Rheumatology, vol. 19, no. 12, pp. 805-817. https://doi.org/10.1038/s41584-023-01045-w

International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative. / Oldroyd, Alexander G. S.; Callen, Jeffrey P.; Chinoy, Hector et al.
In: Nature Reviews Rheumatology, Vol. 19, No. 12, 12.2023, p. 805-817.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening

T2 - an International Myositis Assessment and Clinical Studies Group (IMACS) initiative

AU - Oldroyd, Alexander G. S.

AU - Callen, Jeffrey P.

AU - Chinoy, Hector

AU - Chung, Lorinda

AU - Fiorentino, David

AU - Gordon, Patrick

AU - Machado, Pedro M.

AU - McHugh, Neil

AU - Selva-O’Callaghan, Albert

AU - Schmidt, Jens

AU - Tansley, Sarah L.

AU - Vleugels, Ruth Ann

AU - Werth, Victoria P.

AU - Amato, Anthony A.

AU - Andersson, Helena

AU - Andrade-Ortega, Lilia

AU - Ascherman, Dana

AU - Benveniste, Olivier

AU - Cavagna, Lorenzo

AU - Charles-Shoeman, Christina

AU - Chong, Benjamin F.

AU - Christopher-Stine, Lisa

AU - Clarke, Jennie T.

AU - Crosbie, Emma J.

AU - Crosbie, Philip A. J.

AU - Danoff, Sonye

AU - Dastmalchi, Maryam

AU - de Visser, Marianne

AU - Dellaripa, Paul F.

AU - Diederichsen, Louise Pyndt

AU - Dimachkie, Mazen M.

AU - Ensrud, Erik

AU - Ernste, Floranne

AU - Evans, D. Gareth R.

AU - Fujimoto, Manabu

AU - Garcia-de la Torre, Ignacio

AU - Garcia-Kutzbach, Abraham

AU - Griger, Zoltan

AU - Gupta, Latika

AU - Hudson, Marie

AU - Iannone, Florenzo

AU - Isenberg, David

AU - Jorizzo, Joseph

AU - Kurtz, Helen

AU - Kuwana, Masataka

AU - Limaye, Vidya

AU - Lundberg, Ingrid E.

AU - Mammen, Andrew L.

AU - Mann, Herman

AU - Mastaglia, Frank

AU - McWilliams, Lorna

AU - Mecoli, Christopher A.

AU - Meloni, Federica

AU - Miller, Frederick W.

AU - Moghadam-Kia, Siamak

AU - Moiseev, Sergey

AU - Muro, Yoshinao

AU - Nagy-Vincze, Melinda

AU - Nayler, Clive

AU - Needham, Merrilee

AU - Nishino, Ichizo

AU - Oddis, Chester V.

AU - Paik, Julie J.

AU - Raaphorst, Joost

AU - Rider, Lisa G.

AU - Rojas-Serrano, Jorge

AU - Saketkoo, Lesley Ann

AU - Schiffenbauer, Adam

AU - Shinjo, Samuel Katsuyuki

AU - Shobha, Vineeta

AU - Song, Yeong-Wook

AU - Tillett, Tania

AU - Troyanov, Yves

AU - van der Kooi, Anneke J.

AU - Mercado, M. nica V. zquez-Del

AU - Vencovsky, Jiri

AU - Wang, Qian

AU - Ytterberg, Steven

AU - Aggarwal, Rohit

N1 - Funding Information: This Evidence-Based Guideline was developed and conducted under the auspices of the International Myositis Assessment and Clinical Studies Group (IMACS). R.A. conceived the guideline development process. A.G.S.O. carried out survey question design, distribution and response collation. A.G.S.O and R.A. led the preparation of the manuscript, which was critically appraised and amended by all co-authors. All co-authors completed the surveys that led to the formation of the recommendations. The authors would like to acknowledge A.B. Allard, M.D. George, K. Kolstad, D.J.B. Kurtzman and A. Postolova, who provided input on the systematic literature review and meta-analysis, which formed key evidence for the development of the recommendations. The authors would like to acknowledge the invaluable input from three patient partners (two of whom are listed as authors, one of whom opted to remain anonymous) during the guideline planning, development and manuscript writing. The authors thank members of the IMACS Scientific Committee for critical reading of the manuscript. The authors thank H. Kim and I. Pinal Fernández for critical reading of the manuscript and for providing helpful comments as part of the NIH internal review process. This report includes independent research supported by the National Institute for Health Research (NIHR) Biomedical Research Centre Funding Scheme. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, NIHR or the Department of Health and Social Care. A.G.S.O is supported by funding from the NIHR Clinical Lectureship Scheme. A.G.S.O, H.C., E.J.C., D.G.R.E., L.McW. and P.A.J.C are supported by the NIHR Manchester Biomedical Research Centre (NIHR203308). P.M.M is supported by funding from the NIHR University College London Hospitals Biomedical Research Centre. S.L.T. is supported by funding from the Bath Institute of Rheumatic Diseases. E.J.C. is supported by an NIHR Advanced Fellowship (NIHR300650). This research was supported in part by the Intramural Research Programs of the NIH, National Institute of Environmental Health Sciences (to L.G.R., F.W.M. and A.S.), and National Institute of Arthritis and Musculoskeletal and Skin Diseases (to A.L.M.). J.J.P. is supported by funding from the NIH (K23AR073927). M.V.-D.M. is supported by funding from Fondo de Desarrollo Cientifico (FODECIJAL) 2019 from Consejo Estatal de Ciencia y Tecnología de Jalisco (COECYTJAL, 1702512-8152). J.V. is supported by funding from the Czech Ministry of Health — Conceptual Development of Research Organization 00023728 (Institute of Rheumatology). Publisher Copyright: © 2023, Springer Nature Limited.

PY - 2023/12

Y1 - 2023/12

N2 - Adult-onset idiopathic inflammatory myopathy (IIM) is associated with an increased cancer risk within the 3 years preceding and following IIM onset. Evidence- and consensus-based recommendations for IIM-associated cancer screening can potentially improve outcomes. This International Guideline for IIM-Associated Cancer Screening provides recommendations addressing IIM-associated cancer risk stratification, cancer screening modalities and screening frequency. The international Expert Group formed a total of 18 recommendations via a modified Delphi approach using a series of online surveys. First, the recommendations enable an individual patient’s IIM-associated cancer risk to be stratified into standard, moderate or high risk according to the IIM subtype, autoantibody status and clinical features. Second, the recommendations outline a ‘basic’ screening panel (including chest radiography and preliminary laboratory tests) and an ‘enhanced’ screening panel (including CT and tumour markers). Third, the recommendations advise on the timing and frequency of screening via basic and enhanced panels, according to risk status. The recommendations also advise consideration of upper or lower gastrointestinal endoscopy, nasoendoscopy and 18F-FDG PET–CT scanning in specific patient populations. These recommendations are aimed at facilitating earlier IIM-associated cancer detection, especially in those who are at a high risk, thus potentially improving outcomes, including survival.

AB - Adult-onset idiopathic inflammatory myopathy (IIM) is associated with an increased cancer risk within the 3 years preceding and following IIM onset. Evidence- and consensus-based recommendations for IIM-associated cancer screening can potentially improve outcomes. This International Guideline for IIM-Associated Cancer Screening provides recommendations addressing IIM-associated cancer risk stratification, cancer screening modalities and screening frequency. The international Expert Group formed a total of 18 recommendations via a modified Delphi approach using a series of online surveys. First, the recommendations enable an individual patient’s IIM-associated cancer risk to be stratified into standard, moderate or high risk according to the IIM subtype, autoantibody status and clinical features. Second, the recommendations outline a ‘basic’ screening panel (including chest radiography and preliminary laboratory tests) and an ‘enhanced’ screening panel (including CT and tumour markers). Third, the recommendations advise on the timing and frequency of screening via basic and enhanced panels, according to risk status. The recommendations also advise consideration of upper or lower gastrointestinal endoscopy, nasoendoscopy and 18F-FDG PET–CT scanning in specific patient populations. These recommendations are aimed at facilitating earlier IIM-associated cancer detection, especially in those who are at a high risk, thus potentially improving outcomes, including survival.

UR - http://www.scopus.com/inward/record.url?scp=85176609027&partnerID=8YFLogxK

U2 - https://doi.org/10.1038/s41584-023-01045-w

DO - https://doi.org/10.1038/s41584-023-01045-w

M3 - Article

C2 - 37945774

SN - 1759-4790

VL - 19

SP - 805

EP - 817

JO - Nature Reviews Rheumatology

JF - Nature Reviews Rheumatology

IS - 12

ER -

International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative

Abstract

Access to Document

Other files and links

Cite this